GSK's rotavirus vaccine as effective as Merck shot

A study has found two doses of GlaxoSmithKline's ($GSK) Rotarix is as effective as a three-shot regimen of Merck's ($MRK) RotaTeq in preventing severe rotavirus-associated gastroenteritis. The data dampen concerns about Rotarix' efficacy raised in an earlier clinical trial and show both vaccines to be effective. News

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.